Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins

Vaccine

Volumn 29, Issue 31, 2011, Pages 4903-4912

  Visciano, M L ^a   Diomede, L ^c   Tagliamonte, M ^a   Tornesello, M L ^a   Asti, V ^c   Bomsel, M ^b   Buonaguro, F M ^a   Lopalco, L ^c   Buonaguro, L ^a,d  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b INSTITUT COCHIN   (France)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Envelope proteins; HIV; Neutralizing antibodies; Virus Like Particles

Indexed keywords

ANTIBODY; GLYCOPROTEIN GP 140; GLYCOPROTEIN GP 41;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, VIRAL; BACULOVIRIDAE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; INJECTIONS, INTRAPERITONEAL; INSECTS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; VIROSOMES;

EID: 79959734486     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.005     Document Type: Article

References (69)

1. Gheysen D., Jacobs E., de Foresta F., Thiriart C., Francotte M., Thines D., et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 1989, 59:103-112.
2. Delchambre M., Gheysen D., Thines D., Thiriart C., Jacobs E., Verdin E., et al. The GAG precursor of simian immunodeficiency virus assembles into virus-like particles. EMBO J 1989, 8(September (9)):2653-2660.
3. Miyanohara A., Imamura T., Araki M., Sugawara K., Ohtomo N., Matsubara K. Expression of hepatitis B virus core antigen gene in Saccharomyces cerevisiae: synthesis of two polypeptides translated from different initiation codons. J Virol 1986, 59:176-180.
4. Kirnbauer R., Booy F., Cheng N., Lowy D.R., Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992, 89:12180-12184.
5. Bachmann M.F., Zinkernagel R.M. Neutralizing antiviral B cell responses. Annu Rev Immunol 1997, 15:235-270.
6. Bachmann M.F., Rohrer U.H., Kundig T.M., Burki K., Hengartner H., Zinkernagel R.M. The influence of antigen organization on B cell responsiveness. Science 1993, 262(November (5138)):1448-1451.
7. Buonaguro L., Tornesello M.L., Buonaguro F.M. Virus-Like Particles as particulate vaccines. Curr HIV Res 2010, 299-309.
8. Roy P., Noad R. Virus-like particles as a vaccine delivery system: myths and facts. Adv Exp Med Biol 2009, 655:145-158.
9. Tobin G.J., Li G.H., Fong S.E., Nagashima K., Gonda M.A. Chimeric HIV-1 virus-like particles containing gp120 epitopes as a result of a ribosomal frameshift elicit gag- and SU-specific murine cytotoxic T-lymphocyte activities. Virology 1997, 236:307-315.
10. Wagner R., Deml L., Schirmbeck R., Niedrig M., Reimann J., Wolf H. Construction, expression and immunogenicity of chimeric HIV-1 virus-like particles. Virology 1996, 220:128-140.
11. Deml L., Kratochwil G., Osterrieder N., Knuchel R., Wolf H., Wagner R. Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain. Virology 1997, 235:10-25.
12. Buonaguro L., Buonaguro F.M., Tornesello M.L., Mantas D., Beth-Giraldo E., Wagner R., et al. High efficient production of Pr55gag Virus-like Particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Res 2001, 49:35-47.
13. Buonaguro L., Racioppi L., Tornesello M.L., Arra C., Visciano M.L., Biryahwaho B., et al. Induction of neutralizing antibodies and CTLs in Balb/c mice immunized with Virus-like Particles presenting a gp120 molecule from a HIV-1 isolate of clade A (HIV-VLPAs). Antiviral Res 2002, 54:189-201.
14. Buonaguro L., Visciano M.L., Tornesello M.L., Tagliamonte M., Biryahwaho B., Buonaguro F.M. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J Virol 2005, 79:7059-7067.
15. Buonaguro L., Devito C., Tornesello M.L., Schroder U., Wahren B., Hinkula J., et al. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 2007, 25(January (32)):5968-5977.
16. Pilgrim A.K., Pantaleo G., Cohen O.J., Fink L.M., Zhou J.Y., Zhou J.T., et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 1997, 176(October (4)):924-932.
17. Richman D.D., Wrin T., Little S.J., Petropoulos C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003, 100(April (7)):4144-4149.
18. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., et al. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.
19. Barbas C.F., Bjorling E., Chiodi F., Dunlop N., Cababa D., Jones T.M., et al. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci USA 1992, 89(October (19)):9339-9343.
20. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266(November (5187)):1024-1027.
21. Roben P., Moore J.P., Thali M., Sodroski J., Barbas C.F., Burton D.R. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994, 68(August (8)):4821-4828.
22. Sanders R.W., Venturi M., Schiffner L., Kalyanaraman R., Katinger H., Lloyd K.O., et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 2002, 76(July (14)):7293-7305.
23. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993, 67(November (11)):6642-6647.
24. Stiegler G., Kunert R., Purtscher M., Wolbank S., Voglauer R., Steindl F., et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001, 17(December (18)):1757-1765.
25. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001, 75(November (22)):10892-10905.
26. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326(October (5950)):285-289.
27. Wu X., Yang Z.Y., Li Y., Hogerkorp C.M., Schief W.R., Seaman M.S., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329(August (5993)):856-861.
28. Corti D., Langedijk J.P., Hinz A., Seaman M.S., Vanzetta F., Fernandez-Rodriguez B.M., et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 2010, 5(1):e8805.
29. Gorny M.K., Williams C., Volsky B., Revesz K., Wang X.H., Burda S., et al. Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1. J Virol 2006, 80(July (14)):6865-6872.
30. Bell C.H., Pantophlet R., Schiefner A., Cavacini L.A., Stanfield R.L., Burton D.R., et al. Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. J Mol Biol 2008, 375(January (4)):969-978.
31. Pantophlet R., Wrin T., Cavacini L.A., Robinson J.E., Burton D.R. Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity. Virology 2008, 381(November (2)):251-260.
32. Purtscher M., Trkola A., Gruber G., Buchacher A., Predl R., Steindl F., et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1994, 10(December (12)):1651-1658.
33. Salzwedel K., West J.T., Hunter E. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J Virol 1999, 73(March (3)):2469-2480.
34. Bellamy-McIntyre A.K., Lay C.S., Baar S., Maerz A.L., Talbo G.H., Drummer H.E., et al. Functional links between the fusion peptide-proximal polar segment and membrane-proximal region of human immunodeficiency virus gp41 in distinct phases of membrane fusion. J Biol Chem 2007, 282(August (32)):23104-23116.
35. Munoz-Barroso I., Salzwedel K., Hunter E., Blumenthal R. Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J Virol 1999, 73(July (7)):6089-6092.
36. Zwick M.B., Jensen R., Church S., Wang M., Stiegler G., Kunert R., et al. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 2005, 79(January (2)):1252-1261.
37. Manrique A., Rusert P., Joos B., Fischer M., Kuster H., Leemann C., et al. In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol 2007, 81(August (16)):8793-8808.
38. Montero M., van Houten N.E., Wang X., Scott J.K. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev 2008, 72(March (1)):54-84. table.
39. Crowl R., Seamans C., Lomedico P., McAndrew S. Versatile expression vectors for high-level synthesis of cloned gene products in Escherichia coli. Gene 1985, 38:31-38.
40. Barr P.J., Cousens L.S., Lee-Ng C.T., Medina-Selby A., Masiarz F.R., Hallewell R.A., et al. Expression and processing of biologically active fibroblast growth factors in the yeast Saccharomyces cerevisiae. J Biol Chem 1988, 263:16471-16478.
41. Chakrabarti S., Robert-Guroff M., Wong-Staal F., Gallo R.C., Moss B. Expression of the HTLV-III envelope gene by a recombinant vaccinia virus. Nature 1986, 320:535-537.
42. Lasky L.A., Groopman J.E., Fennie C.W., Benz P.M., Capon D.J., Dowbenko D.J., et al. Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science 1986, 233:209-212.
43. Dewar R.L., Vasudevachari M.B., Natarajan V., Salzman N.P. Biosynthesis and processing of human immunodeficiency virus type 1 envelope glycoproteins: effects of monensin on glycosylation and transport. J Virol 1989, 63:2452-2456.
44. Chertova E., Bess J.J., Crise B.J., Sowder II R.C., Schaden T.M., Hilburn J.M., et al. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 2002, 76:5315-5325.
45. Ratner L., Haseltine W., Patarca R., Livak K.J., Starcich B., Josephs S.F., et al. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 1985, 313:277-284.
46. Li Y., Bergeron J.J., Luo L., Ou W.J., Thomas D.Y., Kang C.Y. Effects of inefficient cleavage of the signal sequence of HIV-1 gp 120 on its association with calnexin, folding, and intracellular transport. Proc Natl Acad Sci USA 1996, 93:9606-9611.
47. Li Y., Luo L., Thomas D.Y., Kang C.Y. Control of expression, glycosylation, and secretion of HIV-1 gp120 by homologous and heterologous signal sequences. Virology 1994, 204:266-278.
48. Boublik Y., Di Bonito P., Jones I.M. Eukaryotic virus display: engineering the major surface glycoprotein of the Autographa californica nuclear polyhedrosis virus (AcNPV) for the presentation of foreign proteins on the virus surface. Biotechnology (NY) 1995, 13:1079-1084.
49. Wang B.Z., Liu W., Kang S.M., Alam M., Huang C., Ye L., et al. Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles. J Virol 2007, 81(October (20)):10869-10878.
50. Ioannou P.A., Amemiya C.T., Garnes J., Kroisel P.M., Shizuya H., Chen C., et al. A new bacteriophage P1-derived vector for the propagation of large human DNA fragments. Nat Genet 1994, 6:84-89.
51. Rovinski B., Haynes J.R., Cao S.X., James O., Sia C., Zolla-Pazner S., et al. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine. J Virol 1992, 66:4003-4012.
52. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
53. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005, 79(August (16)):10108-10125.
54. Tudor D., Derrien M., Diomede L., Drillet A.S., Houimel M., Moog C., et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol 2009, 2(September (5)):412-426.
55. Buonaguro L., Del Gaudio E., Monaco M., Greco D., Corti P., Beth-Giraldo E., et al. Heteroduplex mobility assay and phylogenetic analysis of V3 region sequences of HIV 1 isolates from Gulu - Northern Uganda. J Virol 1995, 69:7971-7981.
56. Buonaguro L., Buonaguro F.M., Russo F., Tornesello M.L., Beth-Giraldo E., Wagner R., et al. A novel gp120 sequence from an HIV-1 isolate of the A clade identified in North Uganda. AIDS Res Hum Retroviruses 1998, 14:1287-1289.
57. Alfsen A., Bomsel M. HIV-1 gp41 envelope residues 650-685 exposed on native virus act as a lectin to bind epithelial cell galactosyl ceramide. J Biol Chem 2002, 277(July (28)):25649-25659.
58. Alfsen A., Yu H., Magerus-Chatinet A., Schmitt A., Bomsel M. HIV-1-infected blood mononuclear cells form an integrin- and agrin-dependent viral synapse to induce efficient HIV-1 transcytosis across epithelial cell monolayer. Mol Biol Cell 2005, 16(September (9)):4267-4279.
59. Magerus-Chatinet A., Yu H., Garcia S., Ducloux E., Terris B., Bomsel M. Galactosyl ceramide expressed on dendritic cells can mediate HIV-1 transfer from monocyte derived dendritic cells to autologous T cells. Virology 2007, 362(May (1)):67-74.
60. Chiodi F., von G.A., Albert J., Fenyo E.M., Gaines H., von S.M., et al. Site-directed ELISA with synthetic peptides representing the HIV transmembrane glycoprotein. J Med Virol 1987, 23(September (1)):1-9.
61. Gnann J.W., Nelson J.A., Oldstone M.B. Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. J Virol 1987, 61(August (8)):2639-2641.
62. Gnann J.W., Schwimmbeck P.L., Nelson J.A., Truax A.B., Oldstone M.B. Diagnosis of AIDS by using a 12-amino acid peptide representing an immunodominant epitope of the human immunodeficiency virus. J Infect Dis 1987, 156(August (2)):261-267.
63. Binley J.M., Sanders R.W., Clas B., Schuelke N., Master A., Guo Y., et al. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 2000, 74(January (2)):627-643.
64. Sanders R.W., Vesanen M., Schuelke N., Master A., Schiffner L., Kalyanaraman R., et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2002, 76(September (17)):8875-8889.
65. Dey A.K., David K.B., Klasse P.J., Moore J.P. Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1. Virology 2007, 360(March (1)):199-208.
66. Crooks E.T., Moore P.L., Franti M., Cayanan C.S., Zhu P., Jiang P., et al. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 2007, 366(September (2)):245-262.
67. Westenberg M., Wang H., IJkel W.F., Goldbach R.W., Vlak J.M., Zuidema D. Furin is involved in baculovirus envelope fusion protein activation. J Virol 2002, 76(January (1)):178-184.
68. Kim M., Qiao Z., Yu J., Montefiori D., Reinherz E.L. Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state. Vaccine 2007, 25(June (27)):5102-5114.
69. Bomsel M., Tudor D., Drillet A.S., Alfsen A., Ganor Y., Roger M.G., et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011, 34(February (2)):269-280.